reason report
encourag buy market miss lt growth
bottom line pullback past month
reflect fall investor sentiment around morgantown
manufactur issu delay new product approv advair
slower ramp new launch copaxon howev
ep beat reiter guidanc indic much
stronger stabl portfolio despit product discontinu
morgantown facil delay gx advair approv
make faster share gain neulasta market pre-fil syring
segment final start see pick-up gener copaxon
share high teen appear tail end
regulatori process gx advair continu believ
ev/ebitda multipl vs peer multipl
remain under-valued consid differenti pipelin
believ drive high singl digit earn growth next
year strengthen balanc sheet leverag like
improv reiter op
chang model tweak time gx advair mid
novemb impact howev fulphila uptak
appear faster initi estim rais
sale contribut although look
color price coheru biosimilar neulasta later week
adjust number howev overal revenu
lower primarili due ou
segment continu spend less estim
accordingli lower sg see lower level
carri outer year overal rais ep
vs prior ep remain
pt
addit takeaway gx advair continu on-going
discuss fda latest updat
final stage label review manag continu believ
ab-rat product reiter import
product long time assumpt launch appropri
conserv given natur complex gener fulphila
see unit week grow manag indic
last week pre-fil syring market
compris almost total neulasta marketplac suppli
in-lin initi plan launch manag
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
gx copaxon manag believ renew focu
pbm payer continu gain traction still
progress make note averag share
progress octob
morgantown manag note within north america
top top gross margin product manufactur
facil signific new product revenu facil project
financi impact remedi
level volum declin
bodi note includ market model epipen
page gx copaxon page gx advair page
also includ latest compani model start page
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
figur chang model
lp estim note number except ep margin
figur chang model continu
lp estim note number except ep margin
note number except ep margin
changevalu changevarianceconsensusactu vs consgeograph areanorth basic dilut non-gaap adjustmentstot one-tim net
sale
sale
sale
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
herceptin approv launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
